- Fellowship - Vanderbilt University School of Medicine (1980-1982), Gastroenterology
- Fellowship - Johns Hopkins Hospital (1979-1980), Hepatology
- Residency - Johns Hopkins Hospital (1977-1979), Internal Medicine
- Medical School - Johns Hopkins University School of Medicine (1973-1977)
Mack Mitchell, M.D.
Vice President Medical Affairs
- Nancy S. and Jeremy L. Halbreich Professorship in Gastroenterology
- Internal Medicine - Digestive and Liver Diseases
- Liver Disease
- Esophageal Disorders
New Patient Appointment Accepting Virtual Visits or 214-645-0595
Biography
Mack Mitchell, M.D., is a Professor of Internal Medicine and Vice President for Medical Affairs at UT Southwestern Medical Center. Dr. Mitchell’s clinical expertise is in digestive and liver diseases, and his research has been focused on alcohol-associated liver disease and alcohol use disorders.
He earned his bachelor’s degree in human biology at Johns Hopkins University and his medical degree at Johns Hopkins University School of Medicine, where he was elected to the Alpha Omega Alpha Honor Medical Society and Phi Beta Kappa. He completed a residency in internal medicine and a fellowship in hepatology at Johns Hopkins; he also completed a fellowship in gastroenterology at Vanderbilt University.
Before coming to UT Southwestern, Dr. Mitchell was the Chief of Gastroenterology and the Medical Director of Ambulatory Services at Johns Hopkins Bayview Medical Center; the Chairman of Internal Medicine at Greater Baltimore Medical Center; and the Chairman of Medicine at Carolinas Medical Center in Charlotte, North Carolina. Dr. Mitchell chose to move from Johns Hopkins to UT Southwestern because of tremendous opportunities to develop and expand clinical services in a growing university medical practice. Before taking on his current role as Vice President for Medical Affairs, he was Vice-Chair of Internal Medicine for Clinical Operations, focused primarily on the ambulatory practice at UT Southwestern.
Dr. Mitchell has served on several national committees, including the Advisory Council and the Board of Scientific Counselors for the National Institute of Alcoholism and Alcohol Abuse, the Research Committee of the American Association for the Study of Liver Diseases, and the Examination Committee of the American Board of Internal Medicine. He is currently President of ABMRF/The Foundation for Alcohol Research and received the Seixas Award for Distinguished Service by the Research Society on Alcoholism. He is a fellow of the American Association for Study of Liver Diseases and the American College of Physicians and a member of the American Gastroenterological Association.
Dr. Mitchell is a general gastroenterologist who treats a wide variety of digestive disorders, ranging from irritable bowel syndrome and gastroesophageal reflux to celiac disease, microscopic colitis, and malabsorption. He also treats a wide range of liver diseases; he has a particular focus on fatty liver diseases, including those related to alcohol use and to metabolic syndrome.
Education & Training
Honors & Awards
- Research Society on Alcoholism 2007, Seixas Award for Distinguished Service
- Alpha Omega Alpha Honor Medical Society, Johns Hopkins School of Medicine
- Phi Beta Kappa, Johns Hopkins School of Medicine
Books & Publications
-
Publications
-
IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.
Szabo G, Mitchell M, McClain CJ, Dasarathy S, Barton B, McCullough AJ, Nagy LE, Kroll-Desrosiers A, Tornai D, Min HA, Radaeva S, Holbein MEB, Casey L, Cuthbert J, Hepatology (Baltimore, Md.) 2022 Mar -
The Practice of Retransplantation for Recurrent Alcohol-associated Liver Disease in the United States Is Uncommon With Acceptable Outcomes.
Cotter TG, Odenwald MA, Lieber SR, Rich NE, Im G, Charlton M, Singal AG, Mitchell MC, Transplantation direct 2022 Mar 8 3 e1297 -
Keratin 18 Is a Diagnostic and Prognostic Factor for Acute Alcoholic Hepatitis.
Vatsalya V, Cave MC, Kong M, Gobejishvili L, Falkner KC, Craycroft J, Mitchell M, Szabo G, McCullough A, Dasarathy S, Radaeva S, Barton B, McClain CJ, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2020 Aug 18 9 2046-2054 -
Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population.
Lazo M, Bilal U, Mitchell MC, Potter J, Hernaez R, Clark JM, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2020 Aug -
Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.
Dasarathy S, Mitchell MC, Barton B, McClain CJ, Szabo G, Nagy LE, Radaeva S, McCullough AJ, Contemporary clinical trials 2020 Jul 96 106094 -
Diagnostic and Prognostic Significance of Complement in Patients with Alcohol-associated Hepatitis.
Fan X, McCullough RL, Huang E, Bellar A, Kim A, Poulsen KL, McClain CJ, Mitchell M, McCullough AJ, Radaeva S, Barton B, Szabo G, Dasarathy S, Rotroff DM, Nagy LE, Hepatology (Baltimore, Md.) 2020 Jun -
Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis.
Saha B, Tornai D, Kodys K, Adejumo A, Lowe P, McClain C, Mitchell M, McCullough A, Dasarathy S, Kroll-Desrosiers A, Barton B, Radaeva S, Szabo G, Hepatology (Baltimore, Md.) 2019 10 70 4 1134-1149 -
Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease.
Jia L, Chang X, Qian S, Liu C, Lord CC, Ahmed N, Lee CE, Lee S, Gautron L, Mitchell MC, Horton JD, Scherer PE, Elmquist JK Molecular metabolism 2018 May -
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.
Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, McCullough A, Mitchell MC, Morgan TR, Nagy L, Radaeva S, Sanyal A, Shah V, Szabo G Gastroenterology 2016 Feb -
Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis.
Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, Veech RL Alcoholism, clinical and experimental research 1990 Apr 14 2 -
Changes in plasma amino acids during sobriety in alcoholic patients with and without liver disease.
Diehl AM, Mitchell MC, Herlong HF, Potter JJ, Wacker L, Mezey E The American journal of clinical nutrition 1986 Oct 44 4
-
IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.
Clinical Focus
- Liver Disease
- Esophageal Disorders
- Gastroenterology
- Liver Transplant Medicine
- Cancer Screening
- Gastroduodenal Diseases
Results: 1 Locations
Digestive Disease Clinic
at Outpatient Building 1801 Inwood Road, 6th Floor, Suite 102Dallas, Texas 75390 214-645-0595 Directions to Digestive Disease Clinic Parking Info for Digestive Disease Clinic
New Patient Appointment Accepting Virtual Visits or 214-645-0595